Patents by Inventor Jean-Francois Pons

Jean-Francois Pons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIVIRAL COMPOUNDS
    Publication number: 20220356148
    Abstract: The present invention relates to novel compounds of general Formula II: wherein the groups X, and R1 to R4 have the meanings given in the description, to a process for preparing these compounds and to their use for treating, preventing or ameliorating viral infections and diseases which are associated with PLA2G16.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 10, 2022
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • Antiviral compounds
    Patent number: 11091428
    Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 17, 2021
    Assignee: HAPLOGEN GMBH
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • ANTIVIRAL COMPOUNDS
    Publication number: 20190225575
    Abstract: The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Application
    Filed: September 12, 2017
    Publication date: July 25, 2019
    Inventors: Wolfgang Fischl, Mark Whittaker, Christopher John Yarnold, Jean-Francois Pons, Mark Anthony Kerry, Patricia Leonie Amouzegh, Inaki Morao, Peter Neville Ingram, Ewa Iwona Chudyk
  • SirT INHIBITORS THAT BIND TO NAD
    Publication number: 20160113903
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 28, 2016
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
  • SirT INHIBITORS THAT BIND TO NAD
    Publication number: 20140163029
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 12, 2014
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
  • SirT inhibitors that bind to NAD
    Patent number: 8486990
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: July 16, 2013
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • SULFONAMIDE COMPOUNDS AND USES THEREOF
    Publication number: 20110152232
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: October 26, 2010
    Publication date: June 23, 2011
    Inventors: Jeffrey O. Saunders, Thomas Coulter, Paul Mortenson, Manuel A. Navia, Jean-Francois Pons
  • Therapeutic compounds and uses thereof
    Patent number: 7897765
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: March 1, 2011
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • Sulfonamide compounds and uses thereof
    Patent number: 7829589
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: November 9, 2010
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Jeffrey O. Saunders, Thomas Coulter, Paul Mortenson, Manuel A. Navia, Jean-Francois Pons
  • SirT Inhibitors That Bind to NAD
    Publication number: 20090306168
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 14, 2009
    Publication date: December 10, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20090264410
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Application
    Filed: February 9, 2009
    Publication date: October 22, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • Therapeutic compounds and uses thereof
    Patent number: 7504506
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: March 17, 2009
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • Aryl dicarboxamides
    Patent number: 7365225
    Abstract: The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: April 29, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Russel J. Thomas, Dominique Swinnen, Jean-Francois Pons, Agnes Bombrun
  • Sulfonamide Compounds and Uses Thereof
    Publication number: 20070270473
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: November 29, 2006
    Publication date: November 22, 2007
    Inventors: Jeffrey Saunders, Thomas Coulter, Paul Mortenson, Manuel Navia, Jean-Francois Pons
  • Sulfonamide compounds and uses thereof
    Publication number: 20060293370
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: June 12, 2006
    Publication date: December 28, 2006
    Inventors: Jeffrey Saunders, Thomas Coulter, Paul Mortenson, Manuel Navia, Jean-Francois Pons
  • Aryl dicarboxamides
    Publication number: 20060189583
    Abstract: The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs.
    Type: Application
    Filed: July 20, 2004
    Publication date: August 24, 2006
    Inventors: Russel Thomas, Dominique Swinnen, Jean-Francois Pons, Agnes Bombrun
  • Methods of treating a disorder
    Publication number: 20060074124
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: March 11, 2005
    Publication date: April 6, 2006
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Sulfonamides and uses thereof
    Publication number: 20050261332
    Abstract: Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 4, 2005
    Publication date: November 24, 2005
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Jean-Francois Pons, Russell Thomas, Manuel Navia, Thomas Coulter, Jeffrey Saunders, Bard Geesaman
  • Methods of treating a disorder
    Publication number: 20050209300
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: September 13, 2004
    Publication date: September 22, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Therapeutic compounds and uses thereof
    Publication number: 20050187237
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Application
    Filed: November 4, 2004
    Publication date: August 25, 2005
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel Navia, Russell Thomas, Jean-Francois Pons, Jeffrey Saunders